Since no irAE signs were observed upon treatment, apparently, the treatment regimen should be modified for more effective response, or OX40L/PPT treatment should be combined with other immunostimulators, or systemic immune checkpoint blockade (ICB) in order to achieve more pronounced effect in this tumor model. This evidence concerns the gene TNFSF4 and neoplasm.